6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
Showing 1 to 10 of 197 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05634876 (ClinicalTrials.gov) | April 2023 | 23/11/2022 | UB-312 in Patients With Synucleinopathies | A Phase 1b Clinical Trial of UB-312 in Patients With Synucleinopathies | Multiple System Atrophy;Parkinson Disease | Biological: UB-312 Injection;Biological: Placebo Injection | NYU Langone Health | NULL | Not yet recruiting | 40 Years | 75 Years | All | 8 | Phase 1/Phase 2 | United States |
| 2 | NCT05357612 (ClinicalTrials.gov) | January 23, 2023 | 20/4/2022 | Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neuro ... | Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neuro ... | Neurodegenerative Diseases;Parkinson Disease;Parkinson Disease Psychosis | Drug: Pimavanserin | Vanderbilt University Medical Center | ACADIA Pharmaceuticals Inc. | Recruiting | 50 Years | 85 Years | All | 75 | Phase 4 | United States |
| 3 | NCT05611372 (ClinicalTrials.gov) | January 1, 2023 | 6/11/2022 | Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease | Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease | REM Sleep Behavior Disorder;Parkinson Disease;Synucleinopathies | Drug: Rasagiline | Second Affiliated Hospital, School of Medicine, Zhejiang University | Beijing Tiantan Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Jiangsu Province Nanjing Brain Hospital;The First Affiliated Hospital of Anhui Medical University;Huashan Hospital;Second Affiliated Hospital of Soochow University;Guizhou Medical University;The First Affiliated Hospital of Guangzhou Medical University;West China Hospital;Sir Run Run Shaw Hospital;The Affiliated Hospital of Hangzhou Normal University;The First Affiliated Hospital of Dalian Medical University;Qilu Hospital of Shandong University;Fujian Medical University Union Hospital Beijing Tiantan Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Jiangsu P ... | Not yet recruiting | 30 Years | 75 Years | All | 732 | Phase 2/Phase 3 | NULL |
| 4 | NCT05635409 (ClinicalTrials.gov) | November 30, 2022 | 15/11/2021 | A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons ... | STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product) STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the S ... | Parkinson Disease | Biological: STEM-PD | Region Skane | Lund University;Cambridge University Hospitals NHS Foundation Trust;University of Cambridge | Recruiting | 50 Years | 75 Years | All | 8 | Phase 1 | Sweden;United Kingdom |
| 5 | NCT05318937 (ClinicalTrials.gov) | July 6, 2022 | 1/4/2022 | A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impai ... | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinso ... | Parkinson Disease;Cognitive Dysfunction | Drug: SAGE-718;Drug: SAGE-718-matching placebo | Sage Therapeutics | NULL | Recruiting | 50 Years | 75 Years | All | 76 | Phase 2 | United States |
| 6 | JPRN-UMIN000047341 | 2022/07/01 | 31/03/2022 | Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease. Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for peop ... | Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease. - Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for people with Parkinson's disease. Randomized controlled trial of the efficacy and feasibility of a mHealth-type dance program for peop ... | Parkinson's disease | The dance exercise group will have one online lesson per week with a coach, 60 minutes (see Appendix for details) and 30 minutes of video dance (movement review and lesson) as a home trainer to perform the exercises. The active control group was instructed to perform stretching, flexibility, and relaxation exercises (excluding strength, balance, aerobic, and functional training) three times a week for 30 minutes per session. These exercises were selected from several physical therapy programs created for persons with Parkinson's disease. The dance exercise group will have one online lesson per week with a coach, 60 minutes (see Appendix ... | Department of Neurology, Fukuoka university | NULL | Pending | 30years-old | 75years-old | Male and Female | 60 | Not selected | Japan |
| 7 | ChiCTR2200059588 | 2022-06-01 | 2022-05-04 | Analysis of speech disorders in patients with Parkinson's disease based on speech signals and machine learning Analysis of speech disorders in patients with Parkinson's disease based on speech signals and machin ... | Analysis of speech disorders in patients with Parkinson's disease based on speech signals and machine learning Analysis of speech disorders in patients with Parkinson's disease based on speech signals and machin ... | Parkinson's Disease | Gold Standard:Parkinson's speech features that can be used for recognition ;Index test:Extract the multi-modal speech features of Parkinson's patients using the developed speech signal processing algorithm ; GoldStandard:Parkinson's speech features that can be used for recognition ;Index test:Extract the mu ... | Provincial Government Hospital in Jiangsu Province | NULL | Pending | 18 | 75 | Both | Target condition:200;Difficult condition:0 | N/A | China |
| 8 | NCT05424276 (ClinicalTrials.gov) | May 23, 2022 | 10/6/2022 | A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease | A Phase 2 Study of IkT-148009 in Untreated Parkinson's Disease | Parkinson Disease | Drug: IkT-148009;Drug: Placebo | Inhibikase Therapeutics, Inc. | NULL | Recruiting | 30 Years | 75 Years | All | 120 | Phase 2 | United States |
| 9 | ChiCTR2100049704 | 2022-03-01 | 2021-08-08 | A randomized controlled clinical study of percutaneous electrical stimulation for constipation in Parkinson's disease A randomized controlled clinical study of percutaneous electrical stimulation for constipation in Pa ... | A randomized controlled clinical study of percutaneous electrical stimulation for constipation in Parkinson's disease A randomized controlled clinical study of percutaneous electrical stimulation for constipation in Pa ... | constipation in Parkinson's disease | TEAS group:ST36 percutaneous electrical stimulation was performed daily;sham-TEAS group:Percutaneous electrical stimulation of 5cm near ST36 was performed daily; TEAS group:ST36percutaneous electrical stimulation was performed daily;sham-TEAS group:Percutaneous ... | Binzhou Medical University Hospital | NULL | Pending | 18 | 75 | Both | TEAS group:15;sham-TEAS group:15; | China | |
| 10 | ChiCTR2200056774 | 2022-03-01 | 2022-02-15 | Clinical efficacy and related mechanism of Edaravone and dexborneol in the treatment of newly diagnosed untreated Parkinson's disease patients Clinical efficacy and related mechanism of Edaravone and dexborneol in the treatment of newly diagno ... | Clinical efficacy and related mechanism of Edaravone and dexborneol in the treatment of newly diagnosed untreated Parkinson's disease patients Clinical efficacy and related mechanism of Edaravone and dexborneol in the treatment of newly diagno ... | parkinson’s disease | patient group:Edaravone and dexborneol;Healthy control group:Nil; | nanjing brain hospital | NULL | Recruiting | 30 | 75 | Both | patient group:30;Healthy control group:30; | Phase 4 | China |